Mutated genes included NRAS/KRAS, BRAF, RAF-1, TP53, PIK3CA, PIK3R3, MTOR, FLT1, FLT3, FLT4, EGFR, and SYK, which are known to be frequently mutated in MM and other related blood malignancies (37–39), as well as to have a therapeutic potential in MM (39) (Tables 2, 3). This evidence concerns the gene TP53 and Miyoshi myopathy.